Solana Company (26H)
XMUN 
Summary
Solana Company (HSDT) Q3 2025 Earnings Call Transcript
Solana Company ( HSDT ) Q3 2025 Earnings Call November 18, 2025 4:30 PM EST Company Participants Choon Wee Chee - Executive Chairman Cosmo Jiang Dane Andreeff - President, CEO & Director Jeff Mathiesen - CFO, Treasurer & Secretary Presentation Operator Hello, and thank you for standing by. Welcome to Solana Company's Third Quarter Operating Results Conference Call.
Helius Medical Technologies, Inc. to Present at the 2024 ThinkEquity Conference
NEWTOWN, Pa., Oct. 18, 2024 – PRISM MediaWire – Helius Medical Technologies, Inc.
Helius Medical Technologies, Inc. (HSDT) Q2 2024 Earnings Call Transcript
Helius Medical Technologies, Inc. (NASDAQ:HSDT ) Q2 2024 Results Conference Call August 12, 2024 4:30 PM ET Company Participants Michelle Bilski - IR Dane Andreeff - President and CO Jeff Mathiesen - CFO Conference Call Participants Anthony Vendetti - Maxim Group Operator Good day, and thank you for standing by. Welcome to the Helius Medical Technologies Second Quarter 2024 Earnings Conference Call [Operator Instructions].
Solana Company Profile
| - Industry | - Sector | Dane Carl Andreeff CEO | XMUN Exchange | US42328V8761 ISIN |
| US Country | 21 Employees | - Last Dividend | 1 Jul 2025 Last Split | 27 Jun 2014 IPO Date |
Overview
Helius Medical Technologies, Inc. stands out as a pioneering company in the realm of neurotechnology with its focus straddling the development, licensing, and procurement of innovative non-implantable technologies aimed at ameliorating symptoms attributable to neurological disorders or injuries. Founded in 2014, this firm has set its base in Newtown, Pennsylvania, marking its commitment towards delivering groundbreaking solutions to enhance neurological health and function.
Products and Services
- Portable Neuromodulation Stimulator (PoNS™)
This avant-garde, non-surgical medical device represents Helius Medical Technologies' flagship offering. It’s specifically engineered for short-term treatment of gait deficits stemming from multiple sclerosis and balance deficits due to mild-to-moderate traumatic brain injury. A key aspect of its application involves concurrent utilization with supervised therapeutic exercises, highlighting its role as a supplementary treatment modality designed to foster improved neurological function.
Contact Information
